The review of modern prospects for the pharmacological treatment of obesity and its complications – The role of GLP- 1, GLP1 / GIP, GLP1 / GIP / GCG receptor agonists

Le résumé fourni par la source

Obesity has emerged as a global epidemic and a chronic neuroendocrine condition, significantly contributing to the prevalence of type 2 diabetes and other metabolic disorders.It is a key predictor of numerous health complications, including diabetic nephropathy, hepatic steatosis and fibrosis, obstructive sleep apnea (OSA), heart failure, degenerative diseases.Furthermore, a higher prevalence of Parkinson's disease has been observed in obese people, which indicates a possible link between the obesity and neurodegenerative diseases.Obese patients are more likely to develop complications such as sleep apnea, hypertension, and hyperlipidemia, thus increasing the risk of cardiovascular events.Lifestyle changes and diet are currently the only accepted treatment of obesity, but researchers have been looking for a good pharmacological therapy to supplement them.The objective of this review is to examine the therapeutic potential of GLP-1 receptor agonists in obesity treatment and its complications, summarizing key clinical trials and outlining future directions for the development of more potent weight-reducing agents, such as Retaglutide.A total of 40 studies retrieved from the New England Medical Journal (nejm.com)were analyzed, focusing on the clinical efficacy of liraglutide, semaglutide, tirzepatide, other less commonly discussed GLP-1 receptor agonists in weight management and metabolic health.This review highlights the expanding role of these agents beyond their primary metabolic applications, offering insights into their evolving therapeutic potential in broader clinical contexts.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.